Cytokine signalling and disease

Bibliography

• ROZWARSKI DA, GRONENBORN AM, CLORE GM et al.: Structural comparisons among the short-chain helical cytokines. Structure (1994) 2(3):159–173.
   PubMed Web of Science ®Google Scholar
• BAZAN JF: Unravelling the structure of IL-2. Science (1992) 257(5068):410–413.
   PubMed Web of Science ®Google Scholar
• POWERS R, GARRETT DS, MARCH CJ et al.: Three-dimensional solution structure of human interleukin-4 by multidimensional heteronuclear magnetic resonance spectroscopy. Science (1992) 256(5064):1673–1677.
   PubMed Web of Science ®Google Scholar
• GARRETT DS, POWERS R, MARCH CJ et al.: Determination of the secondary structure and folding topology of human interleukin-4 using three-dimensional heteronuclear magnetic resonance spectroscopy. Biochemistry (1992) 31(17):4347–4353.
   PubMed Web of Science ®Google Scholar
• BAZAN JF: Haemopoietic receptors and helical cytokines. Immunol Today (1990) 11(10):350–354.
   PubMedGoogle Scholar
• DARNELL JE, Jr.: STATs and gene regulation. Science (1997) 277(5332):1630–1635.
   PubMed Web of Science ®Google Scholar
• IHLE JN: Janus kinases in cytokine signalling. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (1996) 351(1336):159–166.
   PubMed Web of Science ®Google Scholar
• BAZAN JF: Shared architecture of hormone binding domains in Type I and II interferon receptors. CO(1990) 61(5):753–754.
   Google Scholar
• HO AS, LIU Y, KHAN TA et al: A receptor for interleukin 10 is related to interferon receptors. Proc. Natl. Acad. Sci. USA (1993) 90(23):11267–11271.
   PubMed Web of Science ®Google Scholar
• SCHINDLER C, BRUTSAERT S: Interferons as a paradigm for cytokine signal transduction. Cell Ma Life. Sci. (1999) 55(12):1509–1522.
   PubMed Web of Science ®Google Scholar
• WALLACH D, VARFOLOMEEV EE, MALININ NL et al: Tumor necrosis factor receptor and Fas signalling mechanisms. Ann. Rev Immunol (1999) 17:331–367.
   PubMed Web of Science ®Google Scholar
• URIBE L, WEINBERG KL: X-linked SCID and other defects of cytokine pathways. Semin. Hematol (1998) 35(4):299–309.
   PubMed Web of Science ®Google Scholar
• NOGUCHI M, YI H, ROSENBLATT HM et al.: Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Ceil (1993) 73(1):147–157.
   PubMed Web of Science ®Google Scholar
• LEONARD WJ: The defective gene in X-linked severe combined immunodeficiency encodes a shared interleukin receptor subunit: implications for cytokine pleiotropy and redundancy. Curt Opin. Immunol (1994) 6(4):631–635.
   PubMed Web of Science ®Google Scholar
• RUSSELL SM, TAYEBI N, NAKAJIMA H et al.: Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science (1995) 270(5237):797–800.
   PubMed Web of Science ®Google Scholar
• NOGUCHI M, NAKAMURA Y, RUSSELL SM et al.: Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science (1993) 262(5141):1877–1880.
   PubMed Web of Science ®Google Scholar
• RUSSELL SM, KEEGAN AD, HARADA N et al.: Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science (1993) 262(5141):1880–1883.
   PubMed Web of Science ®Google Scholar
• GIRT JG, AHDIEH M, EISENMAN J etal.: Utilisation of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. (1994) 13(12):2822–2830.
   Google Scholar
• KIMURA Y, TAKESHITA T, KONDO M et al.: Sharing of the IL-2 receptor gamma chain with the functional IL-9 receptor complex. mt. Immunol (1995) 7(1):115–120.
   Web of Science ®Google Scholar
• TAYLOR N, CANDOTTI F, SMITH S et al.: Interleukin-4 signalling in B lymphocytes from patients with X-linked severe combined immunodeficiency. J. Biol. Chem. (1997) 272(11):7314–7319.
   PubMed Web of Science ®Google Scholar
• MATTHEWS DJ, CLARK PA, HERBERT J et al.: Function of the interleukin-2 (IL-2) receptor gamma-chain in biologic responses of X-linked severe combined immunodeficient B cells to IL-2, IL-4, IL-13, and IL-15. Blood (1995) 85(1):38–42.
   PubMed Web of Science ®Google Scholar
• RUSSELL SM, JOHNSTON JA, NOGUCHI M et al.: Interaction of IL-2R beta and gamma c chains with Jakl and Jak3: implications for XSCID and XCID. Science (1994) 266(5187):1042–1045.
   PubMed Web of Science ®Google Scholar
• JOHNSTON JA, BACON CM, RIEDY MC et al.: Signalling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency. J. Leukoc. Biol. (1996) 60(4):441–452.
   PubMed Web of Science ®Google Scholar
• CANDOTTI F, OAKES SA, JOHNSTON JA et al.: Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood (1997) 90(10):3996–4003.
   PubMed Web of Science ®Google Scholar
• RUSSELL SM, TAYEBI N NAKAJAMI H et al.: Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science (1995) 270(5237):797–800.
   Google Scholar
• KORPI M, VALIAHO J, VIHINEN M: Structure-function effects in primary immunodeficiencies. Scand. Immunol (2000) 52:226–232.
   PubMed Web of Science ®Google Scholar
• NOTARANGELO LD, GILIANI S, MELLA P et al.: Combined immunodeficiencies due to defects in signal transduction: defects of the gammac-JAK3 signalling pathway as a model. Immunobiology (2000) 202(2):106–19.
   PubMed Web of Science ®Google Scholar
• PUEL A, ZIEGLER SF, BUCKLEY RH,LEONARD WJ: Defective IL7R expression in T-B±NKE severe combined immunodeficiency. Nat. Genet. (1998) 20:394–397.
   PubMed Web of Science ®Google Scholar
• GILMOUR KC, FUJII H, CRANSTON T et al.: Defective expression of the interleukin-2/interleukin-15 receptor beta subunit leads to a natural killer cell-deficient form of severe combined immunodeficiency. Blood (2001) 98(3):877–879.
   PubMed Web of Science ®Google Scholar
• VILLA A, SANTAGATA S, BOZZI F et al: Omenn syndrome: a disorder of Ragl and Rag2 genes." Clin. Immunol (1999) 19(2):87–97.
   Google Scholar
• NOTARANGELO LD, VILLA A, SCHWARZ A: RAG and RAG defects. Curt Opin. Immunol (1999) 11(4):435–442.
   PubMed Web of Science ®Google Scholar
• VIHINEN M, ARREDONDO-VEGA FX, CASANOVA JL et al.: Primary immunodeficiency mutation databases. Adv. Genet. (2001) 43:103–188.
   PubMed Web of Science ®Google Scholar
• FESKE S, DRAEGER R, PETER HH, RAO A: Impaired NFAT regulation and its role in severe combined immunodeficiency. Immunobiology (2000) 202:134–151.
   PubMed Web of Science ®Google Scholar
• DI BACCO A, KEESHAN K, MCKENNA SL et al.: Molecular abnormalities in chronic myeloid leukaemia: deregulation of cell growth and apoptosis. Oncologist (2000) 5(5):405–415.
   PubMedGoogle Scholar
• WARMUTH M, DANHAUSER-RIEDL S, HALLEK M: Molecular pathogenesis of chronic myeloid leukaemia: implications for new therapeutic strategies. Ann. Hematol (1999) 78(2):49–64.
   PubMed Web of Science ®Google Scholar
• SAWYERS CL: Chronic myeloid leukaemia. N Engl. J. Med. (1999) 340(17):1330–1340.
   PubMed Web of Science ®Google Scholar
• DE GROOT RP, RAAIJMAKERS JA, LAMMERS JW et al: STAT5 activation by BCR-Abl contributes to transformation of K562 leukaemia cells. Blood (1999) 94(3):1108–1112.
   PubMed Web of Science ®Google Scholar
• LIN TS, MAHAJAN S, FRANK DA: STAT signalling in the pathogenesis and treatment of leukemias. Oncogene (2000) 19(21):2496–2504.
   PubMed Web of Science ®Google Scholar
• DANIAL NN, ROTHMAN P: JAK-STAT signalling activated by Abl oncogenes. Oncogene (2000) 19(21):2523–2531.
   PubMed Web of Science ®Google Scholar
• DANIAL NN, PERNIS A, ROTHMAN PB: Jak-STAT signalling induced by the v-abl oncogene. Science (1995) 269(5232):1875–1877.
   PubMed Web of Science ®Google Scholar
• NOSAKA T, KITAMURA T: Janus kinases(JAKs) and Signal Transducers and Activators of Transcription (STATs) in hematopoetic cells. Int. J. Hematol (2000) 71:309–319.
   PubMed Web of Science ®Google Scholar
• MIGONE TS, UN JX, CERESETO A et al.: Constitutively activated Jak-STAT pathway in T cells transformed with HTLV- I. Science (1995) 269(5220):79–81.
   PubMed Web of Science ®Google Scholar
• MEYDAN N, GRUNBERGER T, DADI H et al.: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (1996) 379(6566):645–648.
   PubMed Web of Science ®Google Scholar
• JOHNSON JM, HARROD R, FRANCHINI G: Molecular biology and pathogenesis of the human T-cell leukaemia/lymphotropic virus Type-1 (HTLV-1) . kit. I Exp. Pathol (2001) 82(3):135–147.
   PubMed Web of Science ®Google Scholar
• XIA Z, BAER MR, BLOCK AW et al: Expression of signal transducers and activators of transcription proteins in acute myeloid leukaemia blasts. Cancer Res. (1998) 58(14):3173–3180.
   PubMed Web of Science ®Google Scholar
• LIU RY, FAN C, GARCIA R et al.: Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukaemia cell lines. Blood (1999) 93(7):2369–2379.
   PubMed Web of Science ®Google Scholar
• MATUTES E, TAYLOR GP, CAVENAGH J et al.: Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br. .1. Haematol (2001) 113(3):779–784.
   Google Scholar
• TALPAZ M: Interferon-alfa-based treatment of chronic myeloid leukaemia and implications of signal transduction inhibition. Semin. Hematol (2001) 38(3 Suppl. 8):22–27.
   Google Scholar
• OLIVEIRA MR, OHNUMA L, BENDIT I et al.: Interferon-alpha therapy increases Type I insulin-like growth factor receptors expression on lymphoid cells from patients with chronic myelogenous leukaemia. Leak. Res. (2001) 25(8):711–717.
   PubMed Web of Science ®Google Scholar
• DENG M, DALEY GQ: Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukaemia. Blood (2001) 97(11):3491–3497.
   PubMed Web of Science ®Google Scholar
• WALDMANN TA: T-cell receptors for cytokine:targets for immunotherapy of leukaemia/lymphoma. Ann. Omni (2000) 11\(Suppl. 1):101–106.
   Google Scholar
• JORDAN CT, UPCHURCH D, SZILVASSY SJ et al.: The interleukin 3 receptor alpha chain is a unique marker for human acute myelogenous leukaemia stem cells. Leukemia (2000) 14(10):1777–1784.
   PubMed Web of Science ®Google Scholar
• GAO B, SHEN X, KUNOS G et al: Constitutive activation of JAK-STAT3 signalling by BRCA1 in human prostate cancer cells. FEBS Lett. (2001) 488(3):179–184.
   PubMed Web of Science ®Google Scholar
• SCHMETZER HM, BRAUN S, WIESNER D, DUELL T, GERHARTZ HH, MITTERMUELLER J: Gene rearrangements in bone marrow cells of patients with acute myelogenous leukaemia. Acta Haematol (2000) 103(3):125–134.
   PubMed Web of Science ®Google Scholar
• BRAUN SW, GERHARTZ HH, SCHMETZER HM: Influence of cytokines and autologous lymphokine-activated killer cells on leukaemia bone marrow cells and colonies in aml. Acta Haematol (2001) 105(4):209–221.
   PubMed Web of Science ®Google Scholar
• TAO M, LI B, NAYINI Jet al.: In vivo effects of IL-4, IL-10, and amifostine on cytokine production in patients with acute myelogenous leukaemia. Leak. Lymphoma (2001) 41(1–2):161–168.
   Google Scholar
• GALON J, AKSENTIJEVICH I, MCDERMOTT MF et al: TNFRSF1A mutations and autoinflammatory syndromes. Curt: Opin. Immunol (2000) 12(4):479–486.
   PubMed Web of Science ®Google Scholar
• MCDERMOTT MF, AKSENTIJEVICH I, GALON J et al.: Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell (1999) 97(1):133–144.
   PubMed Web of Science ®Google Scholar
• ESPEVIK T, SHALABY R, LIABAKK NB et al.: The role of TNF in regulation of cell function. Scand. Gin. Lab. Invest. Suppl (1990) 202:160.
   PubMed Web of Science ®Google Scholar
• MULLER JM, ZIEGLER-HEITBROCK HW, BAEUERLE PA: Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology. (1993) 187(3-5):233–256.
   PubMed Web of Science ®Google Scholar
• GALON J, ASKENTIJEVICH I, MCDERMOTT ME O'SHEA JJ, KASTNER DL: TNFRSF1A mutations and autoinflammatory syndromes. Curt: Opin. Immunol. (2000) 12(4):479–486.
   PubMed Web of Science ®Google Scholar
• NIGROVIC PA, SUNDEL P: Treatment of TRAPS with etanercept: use in pediatrics. Gin. Exp. Rheumatol (2001) 19(4):484–485.
   PubMed Web of Science ®Google Scholar
• DREWE E, MCDERMOTT EM, POWELL RJ: Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl. J. Med. (2000) 343(14):1044–1045.
   PubMed Web of Science ®Google Scholar
• HUGHES AE, RALSTON SH, MARKEN J et al.: Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat. Genet. (2000) 24(1):45–48.
   PubMed Web of Science ®Google Scholar
• RODAN GA, MARTIN TJ: Therapeutic Approaches to Bone Diseases. Science (2000) 289(5484):1508–1514.
   PubMed Web of Science ®Google Scholar
• NEURATH MF, FUSS I, PASPARAKIS M et al.: Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur. Immunol (1997) 27(7):1743–1750.
   PubMed Web of Science ®Google Scholar
• MANNEL DN, ECHTENACHER B: TNF in the inflammatory response. Chem. Immunol (2000) 74:141–161.
   PubMedGoogle Scholar
• VAN ASSCHE G, RUTGEERTS P: Anti-TNF agents in Crohn's disease. Expert Opin. Investig. Drugs (2000) 9(1):103–111.
   PubMed Web of Science ®Google Scholar
• HUGOT JP, CHAMAILLARD M, ZOUALI H et al.: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 411(6837):599–603.
   PubMed Web of Science ®Google Scholar
• OGURA Y, BONEN DK, INOHARA Net al.: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 411(6837):603–606.
   Google Scholar
• BRENNAN FM, GIBBONS DL, MITCHELL T et al.: Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur. ImmunoL (1992) 22(7):1907–1912.
   PubMed Web of Science ®Google Scholar
• COPE AP, ADERKA D, DOHERTY M et al.: Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritic Rheum. (1992) 35(10):1160–1169.
   PubMed Web of Science ®Google Scholar
• MAINI RN, TAYLOR PC: And-cytoldne 651 therapy for rheumatoid arthritis. Ann. Rev Med. (2000) 51:207–229.
   PubMed Web of Science ®Google Scholar
• TAYLOR PC: Anti-tumor necrosis factortherapies. Carr: Opin. Rheumatol (2001) 13(3):164–169.
   PubMed Web of Science ®Google Scholar
• FELDMANN M, MAINI RN: Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Ann. Rev Immunol (2001) 19:163–196.
   Google Scholar
• OPAL SM, FISHER CJ, Jr., DHAINAUT JF et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a Phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleulkin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med. (1997) 25(7):1115–1124.
   Google Scholar
• YANG RB, MARK MR, GRAY A et al: Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature (1998). 395(6699):284–288.
   PubMed Web of Science ®Google Scholar
• SCHUSTER JM, NELSON P: Toll receptors:an expanding role in our understanding of human disease.' Leukoc. Biol. (2000) 67:767–773.
   PubMed Web of Science ®Google Scholar
• MUZIO M, POLENTARUTTI N, BOSISIO D et al: Toll-like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes.' Leukoc. Biol. (2000) 67(4):450–456.
   Google Scholar
• BOWIE A, O'NEILL LA: The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products.' Leukoc. Biol. (2000) 67(4):508–514.
   Google Scholar
• ROCK FL, HARDIMAN G, TIMANS JC et al.: A family of human receptors structurally related to Drosophila Toll. Proc. Natl. Acad. Sci. USA (1998) 95(2):588–593.
   PubMed Web of Science ®Google Scholar
• FITZGERALD KA, O'NEILL LA: The role of the interleukin-1/Toll-like receptor superfamily in inflammation and host defence. Microbes Infect. (2000) 2(8)933–943.
   Google Scholar
• MUZIO M, POLENTARUTTI N, BOSISIO D et al: Toll-like receptor family and signalling pathway. Biochem. Soc. Trans. (2000) 28(5):563–566.
   PubMed Web of Science ®Google Scholar
• HARDIMAN G, ROCK FL, BALASUBRAMANIAN S et al: Molecular characterisation and modular analysis of human MyD88. Oncogene (1996) 13(11):2467–2475.
   PubMed Web of Science ®Google Scholar
• HARDIMAN G, JENKINS NA, COPELAND NG et al.: Genetic structure and chromosomal mapping of MyD88. Genomics (1997) 45(2): 332–339.
   PubMed Web of Science ®Google Scholar
• BOWIE A, KISS-TOTH E, SYMONS JAet al.: A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signalling. Proc. Natl. Acad. Sci. USA (2000) 97(18):10162–10167.
   Google Scholar
• O'NEILL L: The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defence [In Process Citation]. Biochem. Soc. Trans. (2000) 28(5):557–563.
   PubMed Web of Science ®Google Scholar
• WESCHE H, HENZEL WJ, SHILLINGLAW W et al.: MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity (1997) 7(6):837–847.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI O, HOSHINO K, KAWAI T et al.: Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity (1999) 11(4):443–451.
   PubMed Web of Science ®Google Scholar
• SATO S, NOMURA F, KAWAI T et al.: Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signalling pathways.' Immunol (2000) 165(12):7096–7101.
   Web of Science ®Google Scholar
• RHEE SH, HWANG D: Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase. Biol. Chem. (2000) 275(44):34035–34040.
   Web of Science ®Google Scholar
• MUZIO M, BOSISIO D, POLENTARUTTI N et al: Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. Immunol. (2000) 164(11):5998–6004.
   Web of Science ®Google Scholar
• VISINTIN A, MAZZONI A, SPITZERJH et al.: Regulation of Toll-like receptors in human monocytes and dendritic cells. .1 Immunol. (2001) 166(1):249–255.
   Google Scholar
• WAAGE A, HALSTENSEN A, SHALABY R et al.: Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response. I Exp. Med. (1989) 170(6):1859–1867.
   Google Scholar
• SHALABY MR, WAAGE A, AARDEN Let al.: Endotwdn, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production M vivo. Clin. Immunol bninunopathol (1989) 53(3):488–498.
   Google Scholar
• FISHER CJ, Jr., AGOSTI JM, OPAL SM et al.: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl. I Med. (1996) 334(26):1697–1702.
   Google Scholar
• ZENI F, FREEMAN B, NATANSON C: Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Grit. Care Med. (1997) 25(7):1095–1100.
   PubMed Web of Science ®Google Scholar
• LAMMAS DA, CASANOVA JL, KUMARARATNE DS: Clinical consequences of defects in the IL-12-dependent interferon gamma pathway. Clin. Exp. Immunol (2000) 121:417–425.
   PubMed Web of Science ®Google Scholar
• KERR IM, STARK GR: The antiviral effects of the interferons and their inhibition. I Interferon Res. (1992) 12(4):237–240. loft STARK GR, KERR IM, WILLIAMS BR et al.: How cells respond to interferons. Ann. Rev Biochem. (1998) 67:227–264.
   Google Scholar
• HAQUE SJ, WILLIAMS BR: Signal transduction in the interferon system. Semin.Oncol. (1998) 25(1 Supp1.1):14–22.
   Google Scholar
• CEBULLA CM, MILLER DM, SEDMAK DD: Viral inhibition of interferon signal transduction. Intervirology (1999) 42(5-6):325–330.
   PubMed Web of Science ®Google Scholar
• ALCAMI A, KOSZINOWSKI UH: Viral mechanisms of immune evasion. Immunol Today (2000) 21(9):447–455.
   PubMedGoogle Scholar
• GOODBOURN S, DIDCOCK L, RANDALL RE: Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. I Gen. Viral. (2000) 81 (Pt 10):2341–2364.
   PubMed Web of Science ®Google Scholar
• ACKRILL AM, FOSTER GR, LAXTON CD et al: Inhibition of the cellular response to interferons by products of the adenovirus Type 5 ElA oncogene. Nucleic Acids Res. (1991) 19(16):4387–4393.
   PubMed Web of Science ®Google Scholar
• MCNAIR AN, KERR IM: Viral inhibition of the interferon system. Pharmacol Ther (1992) 56(1):79–95.
   PubMed Web of Science ®Google Scholar
• MAHR JA, GOODING LR Immune evasion by adenoviruses. Immunol Rev (1999) 168:121–130.
   PubMed Web of Science ®Google Scholar
• KALVAKOLANU DV: Virus interception of cytokine-regulated pathways. Trends Microbiol (1999) 7(4):166–171. los. DAVIES MV, ELROY-STEIN O, JAGUS R et al.: The vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2..1. Virol (1992) 66(4):1943–1950.
   Google Scholar
• SMITH GL, VANDERPLASSCHEN A: Extracellular enveloped vaccinia virus. Entry, egress, and evasion. Adv. Exp. Med. Biol. (1998) 440(12):395–414.
   PubMed Web of Science ®Google Scholar
• SPRIGGS MK: One step ahead of the game: viral immunomodulatory molecules. Ann. Rev Immunol. (1996) 14(22):101–130.
   PubMed Web of Science ®Google Scholar
• ALCAMI A, SYMONS JA, COLLINS PD et al.: Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J. Immunol. (1998) 160(2):624–633.
   PubMed Web of Science ®Google Scholar
• TORTORELLA D, GEWURZ BE, FURMAN MH et al.: Viral subversion of the immune system. Ann. Rev Immunol. (2000) 18:861–926.
   PubMed Web of Science ®Google Scholar
• DE LA CHAPELLE A, SISTONEN P, LEHVASLAIHO H et al.: Familial erythrocytosis genetically linked to erythropoietin receptor gene. Lancet (1993) 341(8837):82–84.
   PubMed Web of Science ®Google Scholar
• DE LA CHAPELLE A, TRASKELIN AL, JUVONEN E: Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc. Natl. Acad. ScL USA (1993) 90(10):4495–4499.
   PubMed Web of Science ®Google Scholar
• YOSHIMURA A, ARAI K: Physician Education: the erythropoietin receptor and signal transduction. Oncologist (1996) 1(5)337–339.
   Google Scholar
• FURUKAWA T, NARITA M, SAKAUE M et al.: Primary familial polycythaemia associated with a novel point mutation in the erythropoietin receptor. Br. Haematoi (1997) 99(1):222–227.
   PubMed Web of Science ®Google Scholar
• PELLEYMOUNTER MA, CULLEN MJ, BAKER MB et al.: Effects of the obese gene product on body weight regulation in ob/ob mice. Science (1995) 269(5223):540–543.
   PubMed Web of Science ®Google Scholar
• CLEMENT K, DINA C, BASDEVANT A et al.: A sib-pair analysis study of 15 candidate genes in French families with morbid obesity: indication for linkage with islet 1 locus on chromosome 5q. Diabetes (1999) 48(2):398–402.
   PubMed Web of Science ®Google Scholar
• HAGER J, DINA C, FRANCKE S et al.: A genome-wide scan for human obesity genes reveals a major susceptibility locus on chromosome 10. Nat. Genet. (1998) 20(3):304–308.
   PubMed Web of Science ®Google Scholar
• CLEMENT K, VAISSE C, LAHLOU N et al.: A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature (1998) 392(6674):398–401.
   PubMed Web of Science ®Google Scholar
• PANHUYSEN CI, MEYERS DA, POSTMA DS et al.: The genetics of asthma and atopy. Allergy (1995) 50(11):863–869.
   PubMed Web of Science ®Google Scholar
• MARSH DG: Mapping the genes for IgE production and allergy. Adv. Exp. Med. Biol. (1996) 409:43–53.
   PubMedGoogle Scholar
• CORRY DB, KHERADMAND F: Induction and regulation of the IgE response. Nature (1999) 402(6760 Suppl.):B18–B23.
   Google Scholar
• SHIRAKAWA I, DEICHMANN KA, IZUHARA I et al.: Atopy and asthma: genetic variants of IL-4 and IL-13 signalling. Immunol. Today (2000) 21(2):60–64.
   PubMedGoogle Scholar
• BLEECKER ER, AMELUNG PJ, LEVITT RC et al.: Evidence for linkage of total serum IgE and bronchial hyperresponsiveness to chromosome 5q: a major regulatory locus important in asthma. Clin. Exp. Allergy (1995) 25 (Suppl. 2):84–88. (Discussion:95–96).
   Google Scholar
• POSTMA DS, BLEECKER ER, AMELUNG PJ et al.: Genetic susceptibility to asthma--bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl. J. Med. (1995) 333(14):894–900.
   PubMed Web of Science ®Google Scholar
• XU J, LEVITT RC, PANHUYSEN CI et al.: Evidence for two unlinked loci regulating total serum IgE levels. Am. J. Hum. Genet (1995) 57(2):425–430.
   PubMed Web of Science ®Google Scholar
• MEYERS DA, POSTMA DS, PANHUYSEN CI et al.: Evidence for a locus regulating total serum IgE levels mapping to chromosome 5. Genomics (1994) 23(2):464–470.
   PubMed Web of Science ®Google Scholar
• NICOLAIDES NC, HOLROYD KJ, EWART SL et al.: Interleukin 9: a candidate gene for asthma. Proc. Natl. Acad. Sci. USA (1997) 94(24):13175–13180.
   PubMed Web of Science ®Google Scholar
• TOWNSEND JM, FALLON GP, MATTHEWS JD et al.: IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunio, (2000) 13(4): p. 573–583.
   Web of Science ®Google Scholar
• LEVITT RC, MCLANE MP, MACDONALD D etal.: IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders. I Allergy Clin. Immunol. (1999) 103(5 Pt. 2):5485–5491.
   Google Scholar
• MARSH DG, MEYERS DA: A major gene for allergy - fact or fancy? Nat. Genet. (1992) 2(4):252–254.
   PubMed Web of Science ®Google Scholar
• BROMBACHER F: The role of interleukin-13 in infectious diseases and allergy. Bioessays (2000) 22(7):646–656.
   PubMed Web of Science ®Google Scholar
• CALLARD RE, MATTHEWS DJ, HIBBERT L: IL-4 and IL-13 receptors: are they one and the same? Immunol. Today (1996) 17(3):108–110.
   Google Scholar
• NELMS K, HUANG H, RYAN J et al.: Interleukin-4 receptor signalling mechanisms and their biological significance. Adv. Exp. Med. Biol. (1998) 452:37–43.
   PubMed Web of Science ®Google Scholar
• BARNES KC, FREIDHOFF LR, NICKEL R et al.: Dense mapping of chromosome 12q13.12-q23.3 and linkage to asthma and atopy. I Allergy Clin. Immunol. (1999) 104(2 Pt. 1):485–491.
   Google Scholar